362 related articles for article (PubMed ID: 24995853)
1. Dissolution enhancement and formulation of rapid-release lornoxicam mini-tablets.
Tawfeek HM; Saleem IY; Roberts M
J Pharm Sci; 2014 Aug; 103(8):2470-83. PubMed ID: 24995853
[TBL] [Abstract][Full Text] [Related]
2. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
Hamza Yel-S; Aburahma MH
Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
[TBL] [Abstract][Full Text] [Related]
3. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
4. A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study.
Teaima MH; Abdel-Haleem KM; Osama R; El-Nabarawi MA; Elnahas OS
Drug Des Devel Ther; 2021; 15():4229-4242. PubMed ID: 34675486
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems.
Pan RN; Chen JH; Chen RR
Drug Dev Ind Pharm; 2000 Sep; 26(9):989-94. PubMed ID: 10914324
[TBL] [Abstract][Full Text] [Related]
6. Formulation and evaluation of mini-tablets-filled-pulsincap delivery of lornoxicam in the chronotherapeutic treatment of rheumatoid arthritis.
Hadi MA; Rao NG; Rao AS
Pak J Pharm Sci; 2015 Jan; 28(1):185-93. PubMed ID: 25553695
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
8. Effects of liquisolid formulations on dissolution of naproxen.
Tiong N; Elkordy AA
Eur J Pharm Biopharm; 2009 Nov; 73(3):373-84. PubMed ID: 19679184
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: accelerated stability study and anti-inflammatory and ulcerogenic effects.
El-Setouhy DA; Gamiel AA; Badawi AA; Osman AS; Labib DA
Pharm Dev Technol; 2017 Mar; 22(2):256-265. PubMed ID: 27494155
[TBL] [Abstract][Full Text] [Related]
10. Influence of hydroxypropyl-beta-cyclodextrin complexation on piroxicam release from buccoadhesive tablets.
Jug M; Bećirević-Laćan M
Eur J Pharm Sci; 2004 Feb; 21(2-3):251-60. PubMed ID: 14757497
[TBL] [Abstract][Full Text] [Related]
11. Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations.
Verma MM; Kumar MT; Balasubramaniam J; Pandit JK
Boll Chim Farm; 2003 Apr; 142(3):119-24. PubMed ID: 12806831
[TBL] [Abstract][Full Text] [Related]
12. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
13. Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam.
Li F; Song S; Guo Y; Zhao Q; Zhang X; Pan W; Yang X
Drug Deliv; 2015; 22(4):487-98. PubMed ID: 24524289
[TBL] [Abstract][Full Text] [Related]
14. Novel sustained-release fast-disintegrating multi-unit compressed tablets of lornoxicam containing Eudragit RS coated chitosan-alginate beads.
Aburahma MH; Hamza Yel-S
Pharm Dev Technol; 2011 Aug; 16(4):316-30. PubMed ID: 20307250
[TBL] [Abstract][Full Text] [Related]
15. Solid-state dependent dissolution and oral bioavailability of piroxicam in rats.
Lust A; Laidmäe I; Palo M; Meos A; Aaltonen J; Veski P; Heinämäki J; Kogermann K
Eur J Pharm Sci; 2013 Jan; 48(1-2):47-54. PubMed ID: 23085546
[TBL] [Abstract][Full Text] [Related]
16. A pilot human pharmacokinetic study and influence of formulation factors on orodispersible tablet incorporating meloxicam solid dispersion using factorial design.
Aboelwafa AA; Fahmy RH
Pharm Dev Technol; 2012; 17(1):1-14. PubMed ID: 20550483
[TBL] [Abstract][Full Text] [Related]
17. Development of a mini-tablet of co-grinded prednisone-Neusilin complex for pediatric use.
Lou H; Liu M; Wang L; Mishra SR; Qu W; Johnson J; Brunson E; Almoazen H
AAPS PharmSciTech; 2013 Sep; 14(3):950-8. PubMed ID: 23761262
[TBL] [Abstract][Full Text] [Related]
18. Niosomal gel of lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity.
Kumbhar D; Wavikar P; Vavia P
AAPS PharmSciTech; 2013 Sep; 14(3):1072-82. PubMed ID: 23818079
[TBL] [Abstract][Full Text] [Related]
19. Melt sonocrystallized piroxicam for oral delivery: particle characterization, solid state analysis, and pharmacokinetics.
Gupta PS; Sharma V; Pathak K
Expert Opin Drug Deliv; 2013 Jan; 10(1):17-32. PubMed ID: 23102052
[TBL] [Abstract][Full Text] [Related]
20. Design and in vitro evaluation of novel sustained- release matrix tablets for lornoxicam based on the combination of hydrophilic matrix formers and basic pH-modifiers.
Hamza Yel-S; Aburahma MH
Pharm Dev Technol; 2010; 15(2):139-53. PubMed ID: 19895367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
